It’s the first genetic editing company to file an IPO.
Editas Medicine—a startup backed by Bill Gates and Google Ventures, among others— has filed to become the first gene-editing medical technology company to go public
The Crispr technique, which allows scientists to precisely and easily edit genes that will be passed down to future generations, has been heralded in the scientific community as a revolutionary step into the future of medicine. Some scientists, in a study funded by the Bill and Melinda Gates Foundation, are already proposing to use the technology to wipe out certain species of mosquitos that are the prime carriers of malaria. In December, policy-makers and scientists gathered in Washington, D.C. for a conference to discuss the wide-ranging implications of the technique, where many advised caution in the use of such a powerful tool.